Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Recurrence 7Multiple Myeloma 6Neoplasms 5Burkitt Lymphoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma 4Lymphoma, Non-Hodgkin 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Waldenstrom Macroglobulinemia 2Solid Tumor 2Small Cell Lung Carcinoma 2Sarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neuroblastoma 2Neoplasms, Plasma Cell 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Melanoma 2Medulloblastoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Large Granular Lymphocytic 2Intraocular Lymphoma 2

Interventions

fludarabine 1alovudine 1Cyclophosphamide 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Metastatic Castration-resistant Prostate Cancer × Cyclophosphamide × Clear all
NCT03692663 2022-08-01

Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer

Allife Medical Science and Technology Co., Ltd.

Phase EARLY_PHASE1 Unknown
9 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡